SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-02-12
Accession Number: 0001493152-26-006407
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226006407/forms-1.htm

Chunk 52 of 83
Word Count: 1439
Character Count: 9140

Document Content:

actions, as well as through regular reports directly from officers responsible for oversight of particular risks within our company. Our board of directors believes that full and open communications between management and the board of directors are essential for effective risk management and oversight. Compensation Committee Interlocks and Insider Participation None of our executive officers serves, or in the past has served, as a member of the board of directors or compensation committee, or other committee serving an equivalent function, of any entity that has one or more executive officers who serve as members of our board of directors or our compensation committee. None of the members of our compensation committee is, or has ever been, an officer or employee of our company. Clawback Policy will adopt a compensation recovery policy that is compliant with Nasdaq listing rules as required by the Dodd-Frank Act. Code of Business Conduct and Ethics

or prior to the completion of this offering, we will adopt a written code of business conduct and ethics that applies to our employees,
officers and directors. A current copy of the code will be posted on the Corporate Governance section of our website, which will be located
at www.bioventrix.com. We intend to disclose future amendments to certain provisions of our code of business conduct and ethics,
or waivers of such provisions applicable to any principal executive officer, principal financial officer, principal accounting officer
or controller, or persons performing similar functions, and our directors, on our website identified above or in filings with the SEC.

Involvement
in Certain Legal Proceedings

Except
as otherwise disclosed below, to the best of our knowledge, none of our directors or executive officers has, during
the past ten years:

●	been
convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor
offenses);

●	had
any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business
association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years
prior to that time. Mr. Ravich served as a director of Orchids Paper Products Company from February 2013 to 2018, as well as chairman
of the governance committee and as a member of the audit committee. Orchids Paper Products Company filed for Chapter 11 bankruptcy
on April 1, 2019, in the U.S. Bankruptcy Court for the District of Delaware;

●	been
subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, by any court of competent jurisdiction
or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in
any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be
associated with persons engaged in any such activity;

●	been
found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated
a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;

●	been
the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently
reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged
violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions
or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution,
civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting
mail or wire fraud or fraud in connection with any business entity; or

●	been
the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization
(as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange
Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons
associated with a member.

From
time to time, we may be subject to various legal or administrative claims and proceedings arising in the ordinary course of business.
Litigation or any other legal or administrative proceeding, regardless of the outcome, is likely to result in substantial cost and diversion
of our company’s resources, including our company’s management’s time and attention.

EXECUTIVE
AND DIRECTOR COMPENSATION

The
following table sets forth the aggregate compensation paid to our named executive officers for the fiscal years ended December 31, 2025
and 2024. Individuals we refer to as our “named executive officers” include our Chief Executive Officer and our
other most highly compensated executive officers who were serving as executive officers at the end of the fiscal year ended
December 31, 2025 and whose total compensation for services rendered in all capacities exceeded $100,000 during the fiscal year ended
December 31, 2025.

Summary
Compensation Table

Name
and Principal Position Year Salary
($) Bonus
($) Stock
Awards ($) Option
Awards ($) Non-Equity
Incentive Plan Compensation
($) Nonqualified
Deferred Compensation Earnings ($) All
Other Compensation ($) Total

David
Richmond, Chairman, Co-Chief Executive Officer and Chief Financial Officer 2025 $	300,000 - $	14,668	(2) $	8,900	(4) - - $	36,010	(7) $	359,578

Steve
Chartier, President, Co-Chief Executive Officer and Director 2025 $	375,000 $	50,000 $	14,668	(3) $	9,881	(5) - - $	97,225	(7) $	546,774

Ori
Ben-Yehuda, Chief
Medical Officer 2025 - - $	14,668	(3) $	563	(6) - - $	120,000	(8) $	135,231

(1)	Pay out of unused vacation time

(2)	Restricted stock awards granted in 2024 totaling 194,000 shares with a fair value of $0.80
per share; 175,665 shares vested in 2024 and 18,335 shares vested in 2025

(3)	Restricted stock awards granted in 2024 totaling 110,000 shares with a fair value of $0.80 per
share; 91,665 shares vested in 2024 and 18,335 shares vested in 2025

(4)	Incentive stock options granted in 2025 totaling 271,000 shares with a weighted average fair value
of $0.41 per share; 52,750 shares vested in 2025

(5)	Incentive stock options granted in 2025 totaling 292,000 shares with a weighted average
fair value of $0.40 per share; 59,875 shares vested in 2025

(6)	Non-qualified stock options granted in 2025 totaling 25,000 shares with a weighted average fair
value of $0.60 per share; 938 shares vested in 2025

(7)	Employee benefits including 401(K) match if participating

(8)	Consulting fees as our CMO is a consultant

Employment
Arrangements with our Executive Officers and Directors

entered into employment agreements with each of our named executive officers. Under the agreements, Messrs. Chartier and Richmond
report to our Board, and Dr. Ben-Yehuda reports to Messrs. Chartier and Richmond, our Co-CEOs.

Each
agreement will continue until terminated in accordance with its terms, and provides for (A) an annual base salary paid in accordance
with our normal payroll practices and which may be increased in the discretion of our board of directors, but not reduced, (B) a target
annual bonus equal to 30% for Messrs. Chartier and Richmond and 25% for Dr. Ben-Yehuda, with the actual amount of such bonus determined
in the discretion of our board of directors, based on the achievement of individual and/or company performance goals determined by our
board of directors and payable on the date annual bonuses are paid to our other senior executives, but in no event later than March 15th
of the calendar year following the calendar year in which such annual bonus was earned, provided the applicable executive is employed
in active working status with the company at the time the bonus is paid, (C) eligibility to receive equity-based compensation awards,
as determined by our board for each calendar year during the employment period, (D) eligibility to participate in customary health, welfare
and retirement benefit plans we provide our employees, (E) prompt reimbursement for all reasonable business expenses, and (F) fifteen
vacation days annually.

Under
the employment agreements for Messrs. Chartier and Richmond, if the executive’s employment is terminated by the company without
“cause,” or by the executive for “good reason” (each, as defined in the applicable employment agreement, and
referred to herein as a qualifying termination) then the executive will be entitled to receive severance in an amount equal to one times
the executive’s base salary, as in effect on the termination date, payable over twelve months following the termination date, subject
to the executive executing and not revoking a release of claims in favor of the company.